This page is run by AstraZeneca, a founding partner of the Lung Ambition Alliance. View guidelines: https://nitter.cf/t.co/uwQQpeOgai
Global
Joined January 2021
- Tweets492
- Following91
- Followers2.5K
- Likes613
Pinned Tweet
Follow @LungAmbition for updates on Alliance initiatives dedicated to accelerating advances in #LungCancer care. To view our community guidelines, click below.
Lung Cancer Awareness Month is almost here.
Ahead of #LCAM next month, the Lung Ambition Alliance is preparing to share exciting updates as we work toward eliminating lung cancer as a cause of death.
AstraZeneca is a founding partner of the Lung Ambition Alliance.
As ESMO closes, we’re reflecting on how cancer care has changed over the past 10 years – and what the next decade could bring. Leaders from our partner @AstraZeneca reflect on a decade of progress and the innovations that could help shape the future of cancer care. Watch now.
As excitement builds for #ESMO2026, innovation alone isn't enough. The Lung Cancer Policy Network shares lessons from lung cancer screening programmes across Europe, including ways to improve participation and equitable access. Read more: bit.ly/4zW8MUR
How can clinical innovation help overcome barriers to early detection? Learn how @GuardantHealth's SHIELD LUNG study is evaluating a blood-based test designed to support lung cancer detection alongside existing screening pathways: bit.ly/3Uq3W24
Could microplastic particles play an unseen role in lung health? Studies have detected microplastics in lung samples, but researchers are still working to understand their potential health implications. Read more: bit.ly/46KqP2V
Nearly half of surveyed patients and carers across Europe don't know if a lung cancer screening programme exists in their country. See key findings from @LungCancerEu's 9th Report on why public education is vital for early diagnosis: bit.ly/4yeYyxi
On #WorldLungDay, we reaffirm our mission to accelerate advances in lung cancer survival, improve patient outcomes, and one day eliminate lung cancer as a cause of death.
Discover how we’re turning ambition into action: bit.ly/3Ry34aD
“I don’t let it stop me.” Hear Jan, an early-stage lung cancer patient, reflect on diagnosis, surgery and survivorship, and what it means to return to everyday life after a cancer diagnosis. #WCLC26
Translating policy frameworks into improved patient outcomes takes centre stage at #WCLC26. A new report from @LungPolicy spotlights how global momentum can be mobilised into concrete national action to improve care. Read more: bit.ly/45KZq0i
Did you know that exposure to indoor and outdoor air pollution is associated with up to a 17% increased risk of developing lung cancer? Learn how a new @IASLC brief guides governments on strict policy action: bit.ly/4w6RGAJ
Norway's lung cancer screening pilot shows how a radiology-led model can improve efficiency and drive a shift to early diagnosis. A new @LungPolicy case study explores their blueprint for success. Read the learnings: bit.ly/4gHinrC
New research shows AI-powered microscopy can predict mutations in lung cancer with 96.6% accuracy, potentially cutting test result times from weeks to minutes. This could accelerate access to the right targeted therapies for patients. Read more: bit.ly/4bgI5Qj
Why is lung cancer rising among young, non-smoking women? New research has uncovered a surprising finding that points to the urgent need to investigate environmental risk factors. Learn more:
bit.ly/4fi4hdH
Timed targets are a key tool for improving lung cancer outcomes but are often poorly implemented. A new @LungPolicy brief provides a framework for how health systems can use them effectively to reduce delays and improve care. Read the report: bit.ly/4plCj5o
A lung cancer diagnosis can feel like a maze without a map. Patient navigation provides a guide. We're championing a new patient-led consensus statement calling for navigation to be a standard of care for all, not a 'nice to have'. Read it here: bit.ly/4wCkan2
The benefits of lung cancer screening extend beyond the lungs. Data shows that incidental findings on LDCT scans can flag other potential cancers, strengthening the case for national screening programmes and robust follow-up protocols. See the evidence: bit.ly/4vi6f4T
What if a blood test could predict lung cancer risk years in advance? A protein signature reflecting an altered inflammatory environment that precedes cancer may provide a crucial window for prevention. Learn more: bit.ly/4etJ0gT
A major step forward for lung cancer care in France. The IMPULSION pilot is now live, providing low-dose CT screening for 20,000 people to pave the way for a national programme. Progress in action, driven by partners like @AstraZeneca.
The UAE aims to help more patients with advanced NSCLC access diagnostic technologies like liquid biopsy. Using technology from our partner @GuardantHealth, this initiative supports more informed and personalised treatment decisions. Learn more: bit.ly/4dLhsnZ
One year ago, the @WHO passed a landmark resolution for integrated lung health. Now, the focus must shift from commitment to action, including prioritising national screening programmes to help improve patient outcomes. Read the full statement: bit.ly/4tAQt34